UM ESTUDO SOBRE O MELANOMA METASTÁTICO: AVANÇOS TERAPÊUTICOS E PERSPECTIVAS FUTURAS

Abstract

Metastatic melanoma is one of the most aggressive forms of skin cancer, characterized by high mortality rates and therapeutic resistance. In recent years, significant advances in targeted therapies and immunotherapies have revolutionized disease management, leading to improved response rates and overall survival. This systematic review aimed to analyze the therapeutic advancements and future perspectives in the treatment of metastatic melanoma, focusing on innovative strategies such as immune checkpoint inhibitors, combination therapies, and predictive biomarkers.

The methodology involved a rigorous search of scientific databases, resulting in the selection of 6 articles from an initial pool of 180 identified studies. The findings highlighted that therapies such as the combination of PD-1 and LAG-3 inhibitors, as well as the use of BRAF and MEK inhibitors in patients with BRAF V600 mutations, have demonstrated positive impacts on progression-free survival and disease control. However, challenges remain, including acquired treatment resistance and immune-related adverse effects, underscoring the need for personalized therapeutic approaches based on tumor molecular profiling and patient-specific characteristics.

In conclusion, despite significant advancements, metastatic melanoma remains a clinical challenge that requires increasingly refined therapeutic approaches. The development of new clinical trials and the investigation of predictive biomarkers are essential to optimizing treatment efficacy and minimizing toxicity. Thus, the integration of innovative therapies and personalized strategies may represent a significant breakthrough in improving clinical outcomes and overall survival in patients with metastatic melanoma.